Novavax Appoints Biopharmaceutical Industry Veteran Gregg Alton to Board of Directors
04 November 2020 - 9:32AM
Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology
company developing next-generation vaccines for serious infectious
diseases, today announced the appointment of Gregg Alton,
J.D. to its Board as an independent Director. Mr. Alton
brings extensive industry experience to his role on the Novavax
Board of Directors, including more than 20 years at Gilead
Sciences, where he served in an array of leadership roles across a
portfolio of responsibilities.
Mr. Alton served as Gilead’s interim Chief
Executive Officer from January 2019 until March 2019, before and
after which he was Chief Patient Officer. During his tenure at
Gilead, his wide-ranging roles included leadership of commercial
operations in Europe, Asia, Latin America and Africa, as well as
government affairs, public affairs and global medical affairs. He
also served as General Counsel and Chief Compliance Officer.
“We welcome Gregg’s broad global experience at a
pivotal time for Novavax, as we prepare to launch a Phase 3 trial
in the U.S. for our COVID-19 vaccine candidate, and to progress
NanoFlu toward FDA registration,” said Stanley C. Erck,
President and Chief Executive Officer of Novavax. “Gregg’s
broad perspective across multiple areas of the business and deep
insight in infectious disease will be invaluable as we build our
commercial organization and advance in our mission to promote
improved health globally.”
Prior to joining Gilead, Mr. Alton was an
attorney at the law firm of Cooley Godward, LLP, where he
specialized in corporate finance transactions for healthcare and
information technology companies. He currently serves on the Boards
of Directors of Corcept Therapeutics, Enochian Biosciences, and was
previously on the Boards of Pharmozyme Inc., Celladon Corp. and
Oculus Innovative Sciences.
In addition to his corporate experience, Mr.
Alton has served as a trusted advisor to several health-related
advisory boards, including the President’s Advisory Council on
HIV/AIDS at the U.S. Department of Health and Human Services. He
also participates as a board member for a number of non-profit
organizations, including Black Women’s Health Imperative, AIDSVu
and the Boys and Girls Clubs of Oakland.
Mr. Alton received a bachelor's degree in legal
studies from the University of California at Berkeley and a law
degree from Stanford University.
“I am delighted to join Novavax’ Board of
Directors and look forward to working with my fellow Board members
and Novavax’ management team, who share my passion for helping
protect millions of people across the globe from serious infectious
diseases,” said Mr. Alton.
About NovavaxNovavax,
Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that
promotes improved health globally through the discovery,
development, and commercialization of innovative vaccines to
prevent serious infectious diseases. Novavax is currently
conducting multiple clinical trials for NVX-CoV2373, its vaccine
candidate against the virus that causes COVID-19, including a
pivotal Phase 3 clinical trial in the United Kingdom to evaluate
the efficacy, safety and immunogenicity in individuals aged 18-84
years of age. NanoFlu™, its quadrivalent influenza
nanoparticle vaccine, met all primary objectives in its pivotal
Phase 3 clinical trial in older adults. Both candidate vaccines
incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant
to enhance the immune response and stimulate high levels of
neutralizing antibodies. Novavax is a leading innovator of
recombinant vaccines; its proprietary recombinant technology
platform combines the power and speed of genetic engineering to
efficiently produce highly immunogenic nanoparticles in order to
address urgent global health needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Novavax Forward-Looking
Statements
Statements herein relating to the future
of Novavax and the ongoing development of its vaccine and
adjuvant products are forward-looking
statements. Novavax cautions that these forward-looking
statements are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include those identified under the heading “Risk
Factors” in the Novavax Annual Report on Form 10-K for the year
ended December 31, 2019, and Quarterly Report on
Form 10-Q for the period ended June 30, 2020, as
filed with the Securities and Exchange Commission (SEC).
We caution investors not to place considerable reliance on
forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC, available
at sec.gov, for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this document, and we undertake no
obligation to update or revise any of the statements. Our business
is subject to substantial risks and uncertainties, including those
referenced above. Investors, potential investors, and others should
give careful consideration to these risks and uncertainties.
Contacts:
Investors
Erika Trahan ir@novavax.com
240-268-2022
Media
Brandzone/KOGS Communication
Edna Kaplan kaplan@kogspr.com
617-974-8659
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024